How to Get Rid of Visceral Fat: UK Guide

Visceral fat, the deep abdominal fat surrounding your internal organs, is one of the most clinically significant drivers of cardiometabolic risk. Unlike the fat you can pinch at your waist, visceral fat releases inflammatory chemicals directly into the bloodstream, raising the risk of type 2 diabetes, cardiovascular disease and liver disease. The good news is that visceral fat responds well to targeted lifestyle changes. This article explains how to get rid of visceral fat using evidence-based strategies, including diet, exercise, and where appropriate, clinically supervised weight management medicines available in the UK.

What is visceral fat and why does it matter for your health?

Visceral fat is metabolically active fat stored deep in the abdominal cavity that releases inflammatory chemicals and free fatty acids into the portal circulation, driving insulin resistance, raised blood glucose and increased cardiovascular risk.

Visceral fat is the metabolically active fat stored deep within the abdominal cavity, surrounding organs such as the liver, pancreas and intestines, and it poses significantly greater health risks than subcutaneous fat sitting just beneath the skin. Unlike the fat you can pinch at your waist, visceral fat releases inflammatory chemicals and free fatty acids directly into the portal circulation, which supplies the liver. This process contributes to insulin resistance, raised blood glucose, elevated triglycerides and increased blood pressure.

The health consequences of excess visceral fat are well established. Higher levels are independently associated with an increased risk of type 2 diabetes, cardiovascular disease, metabolic dysfunction-associated steatotic liver disease (MASLD, previously called non-alcoholic fatty liver disease) and certain cancers. The NHS and NICE both recognise central adiposity as a key driver of cardiometabolic risk, which is why waist measurement features prominently in clinical risk assessments alongside body mass index (BMI).

Importantly, visceral fat is not fixed. Because it is highly metabolically active, it also responds relatively well to lifestyle intervention, often reducing more readily than subcutaneous fat in the early stages of a calorie deficit or exercise programme. Understanding what visceral fat is, and why it matters, is the first step towards addressing it effectively.

How do you know if you have too much visceral fat?

Waist circumference is the most practical clinical indicator: NICE recommends thresholds of 94 cm in men and 80 cm in women (White European) to identify increased cardiometabolic risk.

Waist circumference is the most practical clinical indicator of excess visceral fat, and NICE guidance recommends using it alongside BMI to assess cardiometabolic risk.^[18][19] For people of White European background, a waist measurement above 94 cm (37 inches) in men and above 80 cm (31.5 inches) in women indicates increased risk, with substantially increased risk above 102 cm (40 inches) in men and 88 cm (34.5 inches) in women. For South Asian, Chinese and Japanese populations, the commonly used cut-offs are lower: above 90 cm in men and above 80 cm in women for increased risk, reflecting greater cardiometabolic risk at equivalent waist sizes compared with White European populations.^[19] These thresholds are consistent with WHO and International Diabetes Federation (IDF) guidance on ethnicity-specific waist cut-offs.

To measure your waist accurately, the NHS advises finding the midpoint between the bottom of your lowest rib and the top of your hip bone, wrapping a tape measure around this point, and taking the reading after breathing out naturally. Avoid pulling the tape tight or measuring over thick clothing.

Waist-to-hip ratio is another useful proxy. Divide your waist measurement by your hip measurement: a ratio above 0.90 in men or 0.85 in women suggests central adiposity, in line with WHO guidance. Waist-to-height ratio, where a value above 0.5 is considered a risk marker, is increasingly used in research settings and is straightforward to calculate at home.

For a more precise measurement, imaging techniques such as dual-energy X-ray absorptiometry (DEXA) scanning or MRI can quantify visceral fat volume directly, but these are not routinely available on the NHS for this purpose and are generally used in research. Some consumer body composition scales claim to estimate visceral fat using bioelectrical impedance, though their accuracy varies considerably. If you are concerned about your waist measurement or overall cardiovascular risk, speaking to your GP is the appropriate first step, as they can arrange relevant blood tests and a full risk assessment.

What is the most effective way to lose visceral fat?

A sustained calorie deficit combined with at least 150 minutes of moderate aerobic exercise per week is the most effective approach, with resistance training added to preserve lean muscle mass.

A sustained calorie deficit combined with regular physical activity is the most effective approach to reducing visceral fat, and evidence consistently shows that visceral fat responds particularly well to this combination compared with subcutaneous fat. No single intervention works in isolation, and the most durable results come from changes that can be maintained over months and years rather than weeks.

Aerobic exercise has the strongest evidence base for visceral fat reduction. Activities such as brisk walking, cycling, swimming and jogging, performed at moderate to vigorous intensity for at least 150 minutes per week (in line with UK Chief Medical Officers' physical activity guidelines), have been shown in multiple trials to reduce visceral fat even when body weight changes are modest. Adding muscle-strengthening activity on at least two days per week is also recommended. Resistance training adds further benefit by preserving lean muscle mass during a calorie deficit, which supports metabolic rate and long-term weight maintenance.

Dietary quality matters alongside overall calorie intake. Reducing ultra-processed foods, refined carbohydrates and added sugars, while increasing fibre, lean protein and unsaturated fats, supports both calorie control and metabolic health. NICE guidance on obesity management recommends a structured calorie deficit of around 600 kcal per day below estimated requirements as a practical target for most adults.^[18][20] Sleep quality and stress management are often overlooked but are clinically relevant: poor sleep and chronically elevated cortisol both promote visceral fat accumulation.

For people who meet clinical criteria, weight management medicines or, in some cases, bariatric surgery may be considered as adjuncts to lifestyle change. NICE sets out eligibility criteria for both pharmacotherapy and bariatric surgery, including BMI thresholds and the presence of weight-related comorbidities; referrals for surgery are typically made through NHS Tier 3 specialist weight management services. Bolt Pharmacy is a GPhC-registered UK online pharmacy offering online weight-management consultations, with prescriber review and pharmacist support, where clinically appropriate options may be discussed.

Can diet alone get rid of visceral fat, or do you need to exercise too?

Diet alone can reduce visceral fat, but combining a calorie deficit with regular aerobic exercise consistently produces greater reductions and additional metabolic benefits that diet cannot fully replicate.

Diet alone can reduce visceral fat, and for people who are unable to exercise due to physical limitations, a well-structured calorie deficit will still produce meaningful reductions. However, combining dietary change with regular physical activity consistently produces greater reductions in visceral fat than either approach alone, and exercise appears to confer additional metabolic benefits that diet cannot fully replicate.

Several dietary patterns have evidence supporting visceral fat reduction. A Mediterranean-style diet, rich in vegetables, legumes, whole grains, oily fish and olive oil, has been associated with lower visceral fat in observational and intervention studies. Very low calorie diets (VLCDs) and low-carbohydrate diets can produce rapid early reductions in visceral fat, partly through glycogen depletion and reduced liver fat, though long-term adherence is variable. VLCDs should be used only under clinical supervision and for a time-limited period, in line with NICE guidance, and are not appropriate for everyone.^[18][20]

Exercise, particularly aerobic activity, appears to target visceral fat preferentially, even in the absence of significant weight loss. Studies have shown that people who exercise regularly but maintain the same body weight can still reduce visceral fat volume over time. This is clinically important because it means physical activity has value beyond the calories it burns.

Practically speaking, the best dietary approach is one that creates a modest, sustainable calorie deficit (NICE guidance recommends around 600 kcal per day below estimated requirements) while meeting nutritional needs. Combining this with at least 150 minutes of moderate aerobic activity per week, plus muscle-strengthening activity on at least two days per week, as recommended in the UK Chief Medical Officers' physical activity guidelines, gives the strongest evidence base for visceral fat reduction and long-term cardiometabolic benefit.

Do weight loss medicines help reduce visceral fat in the UK?

MHRA-authorised medicines including semaglutide (Wegovy) and tirzepatide (Mounjaro) have shown significant visceral fat reductions in clinical trials and are recommended by NICE as adjuncts to lifestyle change for eligible adults.

Several MHRA-authorised weight management medicines have demonstrated clinically meaningful reductions in visceral fat in clinical trials, and they are recommended by NICE as adjuncts to lifestyle intervention for eligible individuals. These medicines work through different mechanisms but share the common outcome of reducing overall body fat, with visceral fat often showing proportionally greater reductions than subcutaneous fat.

Semaglutide (Wegovy) is a GLP-1 receptor agonist available as a subcutaneous injection. The UK SmPC should be consulted for the current authorised dose range, which includes strengths up to 2.4 mg weekly and a higher 7.2 mg strength that has also received MHRA authorisation; 2.4 mg is not the maximum authorised dose. Clinical trial data from the STEP programme show significant reductions in waist circumference and body weight. Liraglutide (Saxenda) works through a similar mechanism and has been recommended by NICE for weight management in eligible adults; the relevant NICE technology appraisal sets out eligibility and commissioning scope.

Tirzepatide (Mounjaro) is a dual GIP and GLP-1 receptor agonist authorised by the MHRA both for type 2 diabetes and for chronic weight management.^[9][10] Trial data from the SURMOUNT programme show substantial reductions in body weight and waist circumference. Mounjaro is supplied as a multiple-dose KwikPen, with each pen containing four weekly doses.^[15][16] NICE technology appraisal guidance sets out eligibility criteria and commissioning arrangements; local Integrated Care Board (ICB) decisions affect NHS availability.

These medicines are not suitable for everyone. They are not recommended during pregnancy or breastfeeding, and women who are pregnant, planning a pregnancy or breastfeeding should discuss this with their prescriber before starting or continuing treatment. Women of childbearing potential taking tirzepatide should use a non-oral contraceptive method, or add a barrier method to their existing oral contraception, for four weeks after starting treatment and for four weeks after each dose increase, as tirzepatide may reduce the effectiveness of oral contraceptives; this is stated in the UK SmPC.

Common side effects across the GLP-1 class include nausea, vomiting and gastrointestinal discomfort, which are usually transient. Suspected side effects should be reported via the MHRA Yellow Card scheme (available at yellowcard.mhra.gov.uk). Orlistat is a further licensed option for weight management and may be considered where GLP-1-based treatments are not suitable; a prescriber can advise on eligibility.

Mounjaro is one option a prescriber may consider after an online consultation with Bolt Pharmacy, and is only prescribed where clinically appropriate.

How long does it take to see a real reduction in visceral fat?

Meaningful visceral fat reductions can begin within four to twelve weeks of sustained lifestyle change, with waist circumference often reducing before significant weight loss appears on the scales.

Meaningful reductions in visceral fat can begin within four to twelve weeks of sustained lifestyle change, and visceral fat tends to respond earlier and more readily than subcutaneous fat during a calorie deficit. However, the timeline varies considerably depending on the degree of calorie deficit, exercise volume, individual metabolic factors and starting visceral fat burden.

In clinical trials of dietary intervention, significant reductions in waist circumference and liver fat have been observed within eight to twelve weeks on structured programmes. With the addition of regular aerobic exercise, some studies report measurable visceral fat reduction within six to eight weeks, even before substantial changes in body weight are apparent on the scales. This is one reason waist circumference is a more sensitive early marker of progress than weight alone.

For people using MHRA-authorised weight management medicines, visceral fat reductions tend to track overall weight loss, which in major trials such as the STEP (semaglutide) and SURMOUNT (tirzepatide) programmes occurred progressively over 68 to 72 weeks. The greatest rate of loss is typically in the first three to six months, with continued but slower reduction thereafter.

It is worth setting realistic expectations:

• Waist circumference reductions of 2 to 4 cm within the first eight to twelve weeks are achievable with consistent effort

• Sustained loss over six to twelve months produces the most clinically significant improvements in cardiometabolic markers

• Regain of visceral fat can occur rapidly if lifestyle changes are not maintained, underscoring the importance of long-term habits over short-term programmes

If you are not seeing progress after three months of consistent effort, speaking to your GP is advisable. Underlying conditions such as hypothyroidism, insulin resistance or sleep apnoea can impair fat loss and may warrant investigation. Certain medicines, including some antipsychotics and corticosteroids, can also promote weight gain and may be worth reviewing with your GP.

Scientific References

1. A causative link between visceral adiposity and hepatic insulin resistance (Kabir M et al.).
2. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1; Wilding JPH et al.).
3. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss (STEP 4; Rubino D et al.).
4. Once-weekly semaglutide 7·2 mg in adults with obesity – STEP programme (Wharton S et al.).
5. Once-weekly semaglutide 7·2 mg in adults with obesity (Wharton S et al.) – PubMed record.
6. Single-dose 7.2 mg semaglutide (Wegovy) pen approved to treat adult patients with obesity.
7. Medicines regulator approves up to 7.2 mg dose of semaglutide (Wegovy) for patients with obesity only.
8. Wegovy 7.2 mg Solution for injection in pre-filled pen – Summary of Product Characteristics.
9. MHRA authorises diabetes drug Mounjaro (tirzepatide) for weight management and weight loss.
10. Tirzepatide – NHS medicines information.
11. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1; Jastreboff AM et al.).
12. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction (SURMOUNT-4; Aronne LJ et al.).
13. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity (SURMOUNT-5; Aronne LJ et al.).
14. Women on 'skinny jabs' must use effective contraception – MHRA guidance.
15. Mounjaro KwikPen 2.5 mg solution for injection in pre-filled pen – Summary of Product Characteristics.
16. Mounjaro – Product Information (INN-tirzepatide).
17. Four-dose Mounjaro KwikPen approved by MHRA for diabetes and weight management.
18. Overweight and obesity management (NG246).
19. Overweight and obesity management – Identifying and assessing overweight, obesity and central adiposity (NG246 chapter).
20. Overweight and obesity management – Physical activity and diet (NG246 chapter).
21. Physical activity guidelines: UK Chief Medical Officers' report.
22. UK Chief Medical Officers' physical activity guidelines (full guidance document).
23. Physical activity guidelines for adults aged 19 to 64.
24. Semaglutide vs Tirzepatide for Weight Loss in Adults With Overweight or Obesity (Rodriguez PJ et al.).
25. Waist-to-height ratio and cardiovascular risk (Pineda JC et al.).

Frequently Asked Questions